554 related articles for article (PubMed ID: 30181243)
1. Oncogenic RAS isoforms show a hierarchical requirement for the guanine nucleotide exchange factor SOS2 to mediate cell transformation.
Sheffels E; Sealover NE; Wang C; Kim DH; Vazirani IA; Lee E; M Terrell E; Morrison DK; Luo J; Kortum RL
Sci Signal; 2018 Sep; 11(546):. PubMed ID: 30181243
[TBL] [Abstract][Full Text] [Related]
2. Anchorage-independent growth conditions reveal a differential SOS2 dependence for transformation and survival in
Sheffels E; Sealover NE; Theard PL; Kortum RL
Small GTPases; 2021 Jan; 12(1):67-78. PubMed ID: 31062644
[TBL] [Abstract][Full Text] [Related]
3. Reduced HRAS G12V-Driven Tumorigenesis of Cell Lines Expressing KRAS C118S.
Huang L; Counter CM
PLoS One; 2015; 10(4):e0123918. PubMed ID: 25902334
[TBL] [Abstract][Full Text] [Related]
4. A requirement for wild-type Ras isoforms in mutant KRas-driven signalling and transformation.
Bentley C; Jurinka SS; Kljavin NM; Vartanian S; Ramani SR; Gonzalez LC; Yu K; Modrusan Z; Du P; Bourgon R; Neve RM; Stokoe D
Biochem J; 2013 Jun; 452(2):313-20. PubMed ID: 23496764
[TBL] [Abstract][Full Text] [Related]
5. The Sos1 and Sos2 Ras-specific exchange factors: differences in placental expression and signaling properties.
Qian X; Esteban L; Vass WC; Upadhyaya C; Papageorge AG; Yienger K; Ward JM; Lowy DR; Santos E
EMBO J; 2000 Feb; 19(4):642-54. PubMed ID: 10675333
[TBL] [Abstract][Full Text] [Related]
6. PI3K regulation of RAC1 is required for KRAS-induced pancreatic tumorigenesis in mice.
Wu CY; Carpenter ES; Takeuchi KK; Halbrook CJ; Peverley LV; Bien H; Hall JC; DelGiorno KE; Pal D; Song Y; Shi C; Lin RZ; Crawford HC
Gastroenterology; 2014 Dec; 147(6):1405-16.e7. PubMed ID: 25311989
[TBL] [Abstract][Full Text] [Related]
7. Unique dependence on Sos1 in
You X; Kong G; Ranheim EA; Yang D; Zhou Y; Zhang J
Blood; 2018 Dec; 132(24):2575-2579. PubMed ID: 30377195
[TBL] [Abstract][Full Text] [Related]
8. Multiplexed screens identify RAS paralogues HRAS and NRAS as suppressors of KRAS-driven lung cancer growth.
Tang R; Shuldiner EG; Kelly M; Murray CW; Hebert JD; Andrejka L; Tsai MK; Hughes NW; Parker MI; Cai H; Li YC; Wahl GM; Dunbrack RL; Jackson PK; Petrov DA; Winslow MM
Nat Cell Biol; 2023 Jan; 25(1):159-169. PubMed ID: 36635501
[TBL] [Abstract][Full Text] [Related]
9. Calmodulin and IQGAP1 activation of PI3Kα and Akt in KRAS, HRAS and NRAS-driven cancers.
Nussinov R; Zhang M; Tsai CJ; Jang H
Biochim Biophys Acta Mol Basis Dis; 2018 Jun; 1864(6 Pt B):2304-2314. PubMed ID: 29097261
[TBL] [Abstract][Full Text] [Related]
10. Cystine/glutamate antiporter xCT (SLC7A11) facilitates oncogenic RAS transformation by preserving intracellular redox balance.
Lim JKM; Delaidelli A; Minaker SW; Zhang HF; Colovic M; Yang H; Negri GL; von Karstedt S; Lockwood WW; Schaffer P; Leprivier G; Sorensen PH
Proc Natl Acad Sci U S A; 2019 May; 116(19):9433-9442. PubMed ID: 31000598
[TBL] [Abstract][Full Text] [Related]
11. A KRAS GTPase K104Q Mutant Retains Downstream Signaling by Offsetting Defects in Regulation.
Yin G; Kistler S; George SD; Kuhlmann N; Garvey L; Huynh M; Bagni RK; Lammers M; Der CJ; Campbell SL
J Biol Chem; 2017 Mar; 292(11):4446-4456. PubMed ID: 28154176
[TBL] [Abstract][Full Text] [Related]
12. Differential Role of the RasGEFs Sos1 and Sos2 in Mouse Skin Homeostasis and Carcinogenesis.
Liceras-Boillos P; Jimeno D; García-Navas R; Lorenzo-Martín LF; Menacho-Marquez M; Segrelles C; Gómez C; Calzada N; Fuentes-Mateos R; Paramio JM; Bustelo XR; Baltanás FC; Santos E
Mol Cell Biol; 2018 Aug; 38(16):. PubMed ID: 29844066
[TBL] [Abstract][Full Text] [Related]
13. Interactions between wild-type and mutant Ras genes in lung and skin carcinogenesis.
To MD; Rosario RD; Westcott PM; Banta KL; Balmain A
Oncogene; 2013 Aug; 32(34):4028-33. PubMed ID: 22945650
[TBL] [Abstract][Full Text] [Related]
14. Genome-wide CRISPR Screen to Identify Genes that Suppress Transformation in the Presence of Endogenous Kras
Huang J; Chen M; Xu ES; Luo L; Ma Y; Huang W; Floyd W; Klann TS; Kim SY; Gersbach CA; Cardona DM; Kirsch DG
Sci Rep; 2019 Nov; 9(1):17220. PubMed ID: 31748650
[TBL] [Abstract][Full Text] [Related]
15. Galpha16 activates Ras by forming a complex with tetratricopeptide repeat 1 (TPR1) and Son of Sevenless (SOS).
Liu AM; Lo RK; Lee MM; Wang Y; Yeung WW; Ho MK; Su Y; Ye RD; Wong YH
Cell Signal; 2010 Oct; 22(10):1448-58. PubMed ID: 20639119
[TBL] [Abstract][Full Text] [Related]
16. SOS2 Comes to the Fore: Differential Functionalities in Physiology and Pathology.
Baltanás FC; García-Navas R; Santos E
Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34205562
[TBL] [Abstract][Full Text] [Related]
17. An oncogenic KRAS transcription program activates the RHOGEF ARHGEF2 to mediate transformed phenotypes in pancreatic cancer.
Kent OA; Sandí MJ; Burston HE; Brown KR; Rottapel R
Oncotarget; 2017 Jan; 8(3):4484-4500. PubMed ID: 27835861
[TBL] [Abstract][Full Text] [Related]
18. SOS1 and KSR1 modulate MEK inhibitor responsiveness to target resistant cell populations based on PI3K and KRAS mutation status.
Daley BR; Vieira HM; Rao C; Hughes JM; Beckley ZM; Huisman DH; Chatterjee D; Sealover NE; Cox K; Askew JW; Svoboda RA; Fisher KW; Lewis RE; Kortum RL
Proc Natl Acad Sci U S A; 2023 Nov; 120(47):e2313137120. PubMed ID: 37972068
[TBL] [Abstract][Full Text] [Related]
19. Is Nanoclustering essential for all oncogenic KRas pathways? Can it explain why wild-type KRas can inhibit its oncogenic variant?
Nussinov R; Tsai CJ; Jang H
Semin Cancer Biol; 2019 Feb; 54():114-120. PubMed ID: 29307569
[TBL] [Abstract][Full Text] [Related]
20. Interrogating the protein interactomes of RAS isoforms identifies PIP5K1A as a KRAS-specific vulnerability.
Adhikari H; Counter CM
Nat Commun; 2018 Sep; 9(1):3646. PubMed ID: 30194290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]